Enanta Pharmaceuticals | ENTA - Loan Capital


Enanta Pharmaceuticals reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
AstraZeneca USD 25.96B 177M Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Immunic USD 0 0 Jun/2024
Incyte USD 29.41M 785K Mar/2026
Insmed USD 542.22M 1.25M Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Ligand Pharmaceuticals USD 446.19M 702K Dec/2025
Merck USD 46.67B 77M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.45B 7.86B Mar/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025